OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
New fields are being explored to bring novel antibody candidates to the pipeline.
The development of CAR-T therapies for solid tumor cancers presents a myriad of challenges.
The COVID-19 vaccines opened the door to powerful market potential for other nucleic acid-based therapies.
September 29, 2023
Biologics formulation comes with a unique set of challenges, which can be overcome through innovative strategies and good partnerships.
September 27, 2023
Webinar Date/Time: Tue, Oct 17, 2023 10:00 AM EDT
September 20, 2023
Tumour-infiltrating lymphocyte (TIL) therapies offer a new route to target cancer.
September 19, 2023
Maik Jornitz, Principal Consultant, BioProcess Resources LLC, discusses the definition of patient safety and how to implement new technologies into upgraded facilities.
September 18, 2023
The EMA’s Committee for Medicinal Products for Human Use has given a positive opinion on Sandoz’ biosimilar trastuzumab for breast and gastric cancer.
September 15, 2023
Despite its success, clinical and logistical roadblocks to mRNA cancer vaccine development remain.
September 13, 2023
Recipharm will provide analytical and process development capabilities to support toxicology studies, in addition to GLP manufacturing of lipid nanoparticles to capture the active pharmaceutical ingredient, an antigen peptide.
September 11, 2023
The agreement states that Orbit will implement its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumors.
September 02, 2023
Nanoparticles offer the potential for a safer, more effective method of drug delivery to the patient.
Image analysis algorithms coupled with microscopy techniques can be used to characterize aggregates of therapeutic proteins.